Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 2,559 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NLS Pharmaceutics Ltd | NLSP | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.1324 | 07:21:18 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.1324 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 2,559 | - | 0.113 - 1.53 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:21:17 | formt | 559 | $ 0.1324 | USD |
NLS Pharmaceutics Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.29M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NLS Pharmaceutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NLSP Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.1325 | 0.1405 | 0.113 | 0.1303068 | 230,446 | -0.0001 | -0.08% |
| 1 Month | 0.189 | 0.1929 | 0.113 | 0.1455245 | 264,063 | -0.0566 | -29.95% |
| 3 Months | 0.50 | 0.52 | 0.113 | 0.1725251 | 616,264 | -0.3676 | -73.52% |
| 6 Months | 0.51 | 0.7423 | 0.113 | 0.3712135 | 570,618 | -0.3776 | -74.04% |
| 1 Year | 1.47 | 1.53 | 0.113 | 0.492072 | 347,778 | -1.34 | -90.99% |
| 3 Years | 3.51 | 3.89 | 0.113 | 1.35 | 593,208 | -3.38 | -96.23% |
| 5 Years | 2.9965 | 7.35 | 0.113 | 2.64 | 795,856 | -2.86 | -95.58% |
NLS Pharmaceutics Description
| NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. |
